Search This Blog

Wednesday, May 14, 2025

With Trump Touring Gulf, Iran Offers Huge Nuclear Concession

 Update(1920ET)Trump's Gulf tour which so far has emphasized deal-making and 'no more chaos' in the Middle East, looks to be resonating with Tehran, whose leadership is closely following from just across the Persian Gulf.

In a major breaking report, NBC says that "Iran is ready to sign a nuclear deal with certain conditions with President Donald Trump in exchange for lifting economic sanctions, a top advisor to Iran’s supreme leader told NBC News on Wednesday."

This is a surprising and huge development given Iran has long said it can no longer trust the Trump administration, given it was Trump who first pulled the US out of Obama's JCPOA nuclear deal in April 2018. 

NBC cites top Iranian official Ali Shamkhani, importantly who serves as military and nuclear advisor to Iran’s Supreme Leader Ayatollah Ali Khamenei, in the following

He said Iran would commit to never making nuclear weapons, getting rid of its stockpiles of highly-enriched Uranium which can be weaponized, agree to only enrich Uranium to the lower levels needed for civilian use, and allow international inspectors to supervise the process, in exchange for the immediate lifting of all economic sanctions on Iran.   

Asked if Iran would agree to sign an agreement today if those conditions were met, Shamkhani said, “Yes.” 

"It’s still possible. If the Americans act as they say, for sure we can have better relations," Shamkhani said. The top official added, "it can lead to a better situation in the near future."

Again, this is a monumental concession offered by such a high-ranking official deeply involved in nuclear negotiations. The Islamic Republic has consistently cast the enrichment issue as a matter of national sovereignty, but has maintained all along that it does not seek nuclear weapons. Indeed, fatwas going back decades issued by the Ayatallahs have called the nuclear bomb 'unIslamic'.

Secretary of Iran's Supreme National Security Council Ali Shamkhani (right), via Reuters

Trump has already announced the immediate lifting of sanctions on Syria, whose population has suffered through many years of hellish proxy war and a US-led siege and starvation sanctions policy. Is Iran next? Is Trump in the mood for more quick deal-making and major declarations? He's on a roll after all. The White House has certainly been busy presenting that the president is stacking up the wins in the Middle East.

Trump while aboard Air Force One and en route to Qatar had earlier called on Iran "to make the right decision" about its nuclear program "because something's going to happen one way or the other."

"So we'll either do it friendly or we'll do it very unfriendly," Trump warned. "And that won't be pleasant." Tehran seems ready for a major new deal. But it also might have Gaddafi's fate in the back of its mind (who famously gave up his WMD program... and we know what happened years down the line).

* * *

Update(1305ET): President Trump has taken US-Qatar relations to 'another level' by signing a series of deals which boost defense and trade ties. Arms and jets continue to be a focus of Qatar talks, especially Trump's signing a $200 billion deal for an unprecedented order of a whopping 160 American-produced commercial jets.

"So it’s over $200 billion but 160 in terms of the Jets, that’s fantastic," Trump said of the deal involving Qatar Airways reaching an agreement with Boeing and GE Aerospace to acquire Boeing 787 Dreamliner and 777X aircraft powered by GE Aerospace engines. Boeing’s stock rose 1.7% Wednesday immediately after the headlines hit.

Of course defense and arms continue to be a big theme, coming off Trump's Saudi leg of the trip. "Defense Secretary Pete Hegseth also signed agreements regarding defense, including a statement of intent on defense cooperation between the State of Qatar and the United States," reports CNN. "Hegseth also signed offer and acceptance letters for MQ 9B aircrafts and FS-LIDS. Trump signed a joint declaration of cooperation between the State of Qatar and the United States of America." As we said before, this remains the bread and butter of historic US-Gulf relations.

Via Al Jazeera

Among the deals include Qatar acquiring "counter-drone" capabilities from US defense company Raytheon, valued at $1billion, as well as MQ-9B drones from General Atomics, an agreement valued at $2 billion.

We should note that there seems to be some exaggerated numbers being casually tossed about amid the array of headlines coming out of Doha, given especially Qatar's GDP is just over $200 billion... and yet the T-word keeps being used, interestingly enough:

In a statement, the White House has said the agreements signed today between Trump and Qatar’s Emir Sheikh Tamim bin Hamad Al-Thani will “generate an economic exchange worth at least $1.2 trillion”.

The statement pointed to $243.5 in economic deals, which includes Qatar Airways buying Boeing planes, weapons acquisitions, and deals related to natural gas and quantum technologies.

It also said the US and Qatar had signed a statement of intent outlining over $38bn in potential investments including support for burden-sharing at Al Udeid Air Base, as well as future defense capabilities related to air defense and maritime security.

Ambrose Evans-Pritchard has also sounded a tone of skepticism amid the avalanche of breathless "trillion dollar" headlines from the Gulf tour:

At crude near $60 a barrel Saudi Arabia faces fiscal trouble and belt-tightening austerity. At $50 or lower it faces a slow-motion crisis and ultimately an existential threat to its economic model. That fate is no longer a remote tail-risk.

Donald Trump cares little for such hard economic constraints as he visits Saudi Arabia. The petrostates of the Gulf represent a vast pot of money in his pre-modern mind.

He aims to scoop up $1 trillion dollars (£760bn) of Saudi wealth, even more than the $600bn already promised over four years by Crown Prince Mohammed bin Salman. He wants another trillion and a half from the rest of the Gulf.

Good luck with that.

Saudi Arabia’s GDP is barely more than $1 trillion, smaller than the economy of the Netherlands. Saudi per capita income is on a par with Portugal. Trump will have to make do with blockbuster headlines and hope that nobody audits the details.

The International Monetary Fund estimates that Saudi Arabia’s “fiscal break-even cost” is $96 a barrel. That is the Brent price required to fund the kingdom’s cradle-to-grave welfare system and to keep the lid on political dissent.

Via The Telegraph/Capital Economics

Meanwhile, also of note is that on Wednesday Qatar’s central bank governor, Sheikh Bandar bin Mohammed bin Saoud Al Thani, met with billionaire Elon Musk on the sidelines of Trump’s visit.

"We've always liked each other," said Trump of Qatar's head of state.

And for injecting a little geopolitical realism on Qatar as a regional hub of US dirty wars...

* * *

As a last major event while still on the ground in Saudi Arabia, and before embarking for Qatar, President Donald Trump met with Syria's President Ahmed al-Sharaa. This signifies a monumental, historic shift in the entire regional order. We are witnessing the final blood soaked after-effects of the culmination of what was laid out in Seymour Hersh's The Redirection, a policy which began all the way back in the Bush administration.

Sharaa, also known as Abu Mohammed al-Jolani, got his start early in the Syria war as an emissary of Islamic State leader Abu Bakr al-Baghdadi, and later became founder of Syrian al-Qaeda, called Jabhat al-Nusra. The terror group went through several name changes, and is now the ruling Hayat Tahrir al-Sham (HTS) in the wake of Bashar al-Assad's December ouster. The CIA had helped the group take over Idlib in 2015.

Trump had yesterday in a speech before the US-Saudi Investment Forum described that Saudi Crown Prince Mohammed bin Salman and Turkish President Recep Tayyip Erdogan had asked him to remove the long in place sanctions against Syria. Trump expressed hope that the country could become stable again under its new rulers. "The sanctions were brutal and crippling and served as an important — really an important function — nevertheless, at the time. But now it’s their time to shine," he said"So I say, 'Good luck, Syria.' Show us something very special.'" As for 'special'...

Indeed, Jolani/Sharaa, went from head of AQ-linked HTS in Idlib province, which is ruled by Sharia law, to standing in Riyadh alongside the United States president and Saudi crown prince. He actually still has not been removed from the US terrorism list, though the ten million dollar bounty which had been on his head was taken off months ago.

Trump described the terrorism elephant in the room by telling reporters aboard Air Force One just after the meeting that Sharaa was a "young, attractive guy — tough guy" with a "strong past" and that he now has an opportunity to stabilize Syria.

"He's got a real shot at pulling it together," Trump added. Trump had reportedly urged Sharaa to make peace with Israel and join the Abraham Accords. Washington has also been pressing Damascus to protect and respect religious minorities after recent mass killings of Alawites, Druze, and Christians - especially along the coast, in the south, and in some Damascus suburbs.

Saudi Crown Prince Mohammed bin Salman, President Donald Trump and Syrian President Ahmad al-Sharaa in Riyadh today. @PressSec/X

The conservative publication National Review has it right in pointing out the following

Trump’s meeting with Ahmed al-Sharaa is even more extraordinary than an American president meeting with some repugnant branch of the Assad family. Until late December, the U.S. government was willing to pay $10 million for information about al-Sharaa’s location, because he was on the “specially designated global terrorist” list. 

The irony is that the Sharaa meeting happened on the sidelines of the summit of the United States and Gulf Cooperation Council (GCC) members in Riyadh. It was the GCC which early in the Syria proxy war had a big role in funding the anti-Assad jihadist insurgency, which included ISIS and al-Qaeda. 

Qatar especially was a big financier of the Islamists in Syria who beheaded civilians, massacred Christians, and took women as sex slaves. Qatar even hosted "Free Syrian Army" (FSA) training camps, in coordination with the CIA and Western and Gulf intelligence services. FSA commandoes would then often, fresh of this training, take their weapons into Syria and fight right alongside ISIS. We have previously documented this many times.

As for highlights from the readout from the Trump-Sharaa meeting:

Trump told al-Sharaa that he had "a tremendous opportunity to do something historic in his country," the readout said. He urged the Syrian leader to sign on to the Abraham Accords, a framework for Arab states to recognize Israeli sovereignty that the U.S. mediated during Trump's first term.

He also advised al-Sharaa to tell foreign terrorists to leave Syria, deport Palestinian terrorists, help the U.S. prevent the resurgence of the Islamic State terrorist group and assume responsibility for ISIS detention centers in Syria's northeast.

Al-Sharaa affirmed his commitment to Syria's 1974 disengagement with Israel and invited American companies to invest in Syrian oil and gas, the readout said.

On Wednesday Trump landed in Qatar, where as Al Jazeera explains "Regional peace, investments, energy and security cooperation on agenda as US President Donald Trump holds talks with Qatari Emir Sheikh Tamim bin Hamad Al Thani in the Qatari capital Doha during the second leg of his Gulf visit."

An American president has not visited Qatar in more than 20 years. But certainly the two sides became closer in the context of the covert push to overthrow Assad, and to wage proxy war against the 'pro-Iran axis' in the region. Qatar is also home to major regional US military and naval facilities, and is of course an oil and gas hub far beyond its tiny geographic size.

As for another theme which Trump is continued to expected pushing, he said Wednesday: "This is good for Israel" - after reporters asked whether the Netanyahu government is being sidelined in his Gulf trip. "Having a relationship like I have with these countries … I think it’s very good for Israel."

And as for the ongoing Gaza crisis, not much has been said publicly, but it is likely high on the agenda behind closed doors. After all, the White House wants to "be able to say he hit a home run in all three kingdoms – that he was able to build relationships that are going to transcend his presidency. He wants to overwhelm the US press with a success list." Trump is holding talks with the Emir of Qatar.

https://www.zerohedge.com/geopolitical/trump-praises-young-attractive-president-sharaa-founder-al-qaeda-syria-qatar-visit

"Sangamo Strategic Financial Positioning and Regulatory Advancements Justify Buy'

TD Cowen's Ritu Baral has given her Buy rating due to a combination of factors related to Sangamo Biosciences’ financial and strategic positioning. The company has recently secured a $23 million equity raise, which, along with other financial maneuvers, positions them with a pro forma cash balance of approximately $58 million. This financial runway is expected to support operations until the end of the third quarter of 2025, providing a stable foundation for ongoing and future projects.

Additionally, Sangamo Biosciences has made significant progress in their regulatory pathway for the ‘920 gene therapy for Fabry disease. The alignment with the FDA on an accelerated filing process, based on promising early trial data, reduces the need for an expensive and time-consuming confirmatory trial. This strategic advantage could expedite the approval process, enhancing the company’s potential for future revenue growth. These factors contribute to the positive outlook and justify the Buy rating.

US health chief Kennedy clashes with lawmakers over vaccine comments

 Robert F. Kennedy Jr. testified before Congress on Wednesday for the first time since taking the role of U.S. health secretary, facing questions over the firing of thousands of health agency employees and a fast-growing measles outbreak.

Kennedy is testifying before the House of Representatives Appropriations Committee on his department's proposed budget for the 2026 fiscal year, and will do so later on Wednesday before the Senate Health, Education, Labor, and Pensions Committee.

Since he was confirmed as Secretary of Health and Human Services in February, Kennedy has slashed jobs at the nation's top food and drugs regulator, public health agency and biomedical research institute, part of the Trump administration's campaign to shrink the federal workforce.

Kennedy says his top priorities as health secretary include identifying the environmental contributors to autism and tackling rising rates of chronic disease.

Kennedy, who for years has sown doubt over the safety and efficacy of vaccines, has also drawn condemnation from health officials for what they say is a weak endorsement of measles shots during an outbreak that has infected more than 1,000, mostly unvaccinated, people and killed three.

"Measles, a disease eliminated in the United States just decades ago, has now claimed the lives of three Americans, including two children who died needlessly, and over 1,000 are confirmed to have contracted the disease," said Representative Rosa DeLauro, the top Democrat on the Appropriations Committee.

"All while you peddle unfounded and dangerous vaccine skepticism, spread lies and misinformation about people living with autism," she added.

Kennedy's confirmation partially hinged on the vote of HELP Committee Republican Chair Senator Bill Cassidy, a doctor from Louisiana who had expressed wariness about Kennedy's history of anti-vaccine views before clearing the path for his appointment.

Cassidy said at the time he ultimately supported the nomination because Kennedy assured him he would protect vaccine access and promised cooperation with his committee.

Cassidy had called on Kennedy to appear before the committee in early April to explain plans to restructure HHS and lay off 10,000 workers.

The hearing on Wednesday is billed as a session on Kennedy's health-related spending plans under President Donald Trump's budget proposal. The plans include an $18 billion cut to National Institutes of Health funding and $3.6 billion from the Centers for Disease Control and Prevention.

"People instinctively fear change, even when it's from worse to better. But without a clearly defined plan or objective, people will assume the worst," Cassidy will tell Kennedy at the hearing, according to prepared remarks shared by his office.

"Much of the conversation around HHS' agenda has been set by anonymous sources in the media and individuals with a bias against the president," Cassidy will say. "Americans need direct reassurance from the administration, from you Mr. Secretary, that its reforms will make their lives easier, not harder."

Democrats and other critics have portrayed the cuts as a gutting of the country's public health infrastructure. Kennedy told the Appropriations Committee they would save taxpayer dollars and make the department more efficient.

"It could save taxpayers an estimated $1.8 billion per year through a reduction in workforce. Our reductions have focused on aligning HHS staffing levels to reflect the size of HHS prior to the COVID-19 pandemic, which saw around a 15% increase in the number of employees," Kennedy said in his opening statement.

https://www.msn.com/en-us/health/other/us-health-chief-kennedy-faces-lawmakers-questions-on-mass-firings-measles/ar-AA1ELObf

High-dose radiation therapy may spur growth in untreated metastatic tumors

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a surprising phenomenon in which high doses of radiation cause growth in existing metastatic tumors that weren't directly treated with radiation.

Scientists had previously observed that radiation can cause distant tumors to shrink after radiation, known as the "abscopal effect." The UChicago researchers therefore dubbed the new, opposite response the "badscopal effect," as a play on words for when unrelated  grow after radiation.

They believe this unexpected response happens because high-dose radiation increases the production of a protein called amphiregulin by tumor cells that are directly treated with radiation. High amounts of amphiregulin weaken the immune system's ability to fight cancer and make cancer cells better at protecting themselves. The findings point to promising new therapeutic strategies that could lead to more effective treatments for metastatic cancer.

Radiotherapy: A double-edged sword?

Radiotherapy is often used alone or in combination with surgery and chemotherapy to control localized tumors. More recently, radiotherapy has been used to treat cancers that have limited spread, termed "oligometastasis." Scientists believe that radiotherapy activates the immune system, producing regression in tumors at distant sites that are not directly treated with radiation (i.e. the abscopal effect).

However, many patients who receive radiation for oligometastasis or as part of an immunotherapy regimen fail to respond to treatment because of the progression of distant metastasis.

"Our lab postulated that high doses of radiation might actually promote tumor growth at unirradiated sites under certain conditions, potentially accounting for some of these failures," said senior author Ralph Weichselbaum, MD, Chair and Daniel K. Ludwig Distinguished Service Professor of Radiation and Cellular Oncology at UChicago Medicine.

"Studies from the 1940s suggested radiation might cause tumor spread, but that never made sense to me because radiation is a highly effective anti-cancer agent within the tumor bed," Weichselbaum said. "However, the communication between the irradiated site and distant metastatic sites is fascinating."

To investigate this tumor-to-tumor interaction, the research team analyzed biopsy samples from a clinical trial in which patients with diverse histological types were treated with high-dose focused radiotherapy known as Stereotactic Body Radiotherapy (SBRT) and checkpoint blockade (Pembrolizumab). That clinical trial team, led by Steven Chmura, MD, Ph.D., Professor of Radiation and Cellular Oncology and Director of Clinical and Translational Research for Radiation Oncology at UChicago, found that tumors at preexisting metastatic sites increased in size following SBRT, suggesting radiation might promote .

To understand how radiation at the primary site affects distant tumors, researchers led by András Piffkó, MD, a post-doctoral fellow in the Weichselbaum lab, conducted gene expression profiling of patient tumors before and after radiation treatment. They discovered that in tumors that had been treated with radiation, the gene encoding for a protein called amphiregulin was significantly increased.

Amphiregulin binds to the  (EGFR), a widely expressed transmembrane tyrosine kinase, and activates major intracellular signaling pathways governing , proliferation, migration and cell death.

The researchers then studied this effect using animal models of lung and breast cancer. They found that while radiation reduced the number of new metastatic sites, it increased the growth of existing metastases. Radiotherapy significantly upregulated amphiregulin in tumor cells and blood. Blocking amphiregulin with antibodies or eliminating its gene in the tumor cells using the gene-editing technology CRISPR reduced the size of tumors outside of the radiation field.

"Interestingly, the combination of radiation and amphiregulin blockade decreased both tumor size and the number of metastatic sites," Weichselbaum said.

The role of immune suppression

To explore the mechanism further, the researchers analyzed blood samples from a second clinical trial conducted by Chmura, in which lung cancer patients received SBRT either following or at the same time as immunotherapy. They found that failure to decrease amphiregulin following SBRT in the serum of patients was associated with an adverse outcome. Additionally, they found an increase in myeloid cells with immunosuppressive characteristics was associated with metastasis progression and death.

In a previous study published in Cancer Cell, Weichselbaum and team demonstrated that ablating immunosuppressive myeloid cells reduces both the size and frequency of metastasis in animal models. By contrast, in the current study, they saw an increase in immunosuppressive myeloid cells in animals where amphiregulin was highly expressed in tumors and blood following radiation but not in tumors that did not express amphiregulin. Amphiregulin appeared to block the differentiation of myeloid cells, leading to an immunosuppressive phenotype.

In collaboration with Ronald Rock, Ph.D., Associate Professor in the Department of Biochemistry at UChicago, the team discovered that amphiregulin and radiation upregulated CD47, a so-called "don't eat me" signal on tumor cells that blocks the ability of macrophages and myeloid cells to engulf tumor cells.

Blocking amphiregulin and CD47 in combination with radiotherapy resulted in highly effective metastatic control in animal models. The study results indicate a paradigm shift for the use of radiation therapy in patients with locally advanced and metastatic tumors, in which molecules upregulated by radiotherapy could be detected and neutralized. This in turn could lead to a new type of personalized radiotherapy, especially in patients with metastatic disease.

"These results open a whole new way of thinking about the systemic effects of radiotherapy," Weichselbaum said. "Based on these findings, we are planning to conduct a clinical trial to further explore and validate the results."

More information: András Piffkó et al, Radiation-induced amphiregulin drives tumour metastasis, Nature (2025). DOI: 10.1038/s41586-025-08994-0


https://medicalxpress.com/news/2025-05-badscopal-effect-high-dose-therapy.html

Enterovirus infections linked to severe respiratory illness in children without asthma

 The Centers for Disease Control and Prevention (CDC) and seven US pediatric medical centers report a notable association between Enterovirus D68 (EV-D68) and severe respiratory illness in children without prior medical conditions. Children with nonasthma or reactive airway disease (RAD) comorbidities demonstrated an increased likelihood of severe outcomes when hospitalized.

Severe respiratory illness linked to Enterovirus D68 (EV-D68) in children has gained attention in recent years. While EV-D68 typically presents with asthma-like symptoms, severe cases have been associated with acute flaccid myelitis (AFM), a neurologic condition causing limb weakness with unpredictable recovery.

A nationwide outbreak of EV-D68 in 2014 raised concerns about its impact on pediatric respiratory health as AFM cases spiked concurrently. Expanded testing capacity, including EV-D68-specific reverse-transcriptase polymerase-chain-reaction (rRT-PCR) assays, was introduced in select clinical and public health settings. Yet, systematic surveillance remains limited, with data largely drawn from single sites or short-term outbreak investigations.

Significant knowledge gaps remain in understanding the epidemiology of EV-D68-associated respiratory illness across multiple years and geographic locations.

In the study, "Enterovirus D68–Associated Respiratory Illness in Children," published in JAMA Network Open, researchers conducted a cross-sectional study to assess the epidemiology and clinical severity of EV-D68-associated respiratory illness in US children from 2017 to 2022 using a systematic, multi-site surveillance network.

Data from 976 children with laboratory-confirmed EV-D68 was collected across seven  within the New Vaccine Surveillance Network, including Cincinnati, Houston, Kansas City, Nashville, Pittsburgh, Rochester, and Seattle. Research staff collected respiratory specimens using nasal and throat swabs. EV-D68 testing occurred through real-time PCR assays conducted at each site.

Enterovirus infections linked to severe respiratory illness in children without asthma
Enterovirus D68 (EV-D68) Detections Among Rhinovirus (RV) and EV Positive Cases and All Acute Respiratory Infection (ARI) Cases by Care Setting, New Vaccine Surveillance Network (2017-2022). Credit: JAMA Network Open (2025). DOI: 10.1001/jamanetworkopen.2025.9131

Researchers identified 976 cases of EV-D68-associated respiratory illness in children under 18 years, with more than half requiring hospitalization. Among the 536 hospitalized children, 339 received , and 87 were admitted to intensive care units.

Children with nonasthma underlying conditions had significantly higher odds of severe outcomes. Odds of receiving supplemental oxygen were more than twice as high in this group (adjusted odds ratio [aOR], 2.72; 95% CI, 1.43–5.18), and ICU admission was three times more likely (aOR, 3.09; 95% CI, 1.72–5.56). No significant association emerged between asthma history and increased severity outcomes.

Detection peaks in 2018 and 2022 accounted for 92% of confirmed cases. During the pandemic surveillance period (March 1, 2020, to December 31, 2022), increased oxygen use was observed in children with nonasthma conditions (adjusted odds ratio [aOR], 1.61; 95% CI, 1.09–2.38).

No significant association emerged between asthma history and severe outcomes, though asthma-related discharge diagnoses were common among hospitalized children without prior asthma history.

Clinical triage and public health preparedness during Enterovirus outbreaks may require broader focus to include children with nonasthma comorbidities as well as those without prior medical conditions. Asthma history did not significantly correlate with severe outcomes but remains a clinical concern given the asthma-like presentation of Enterovirus infections.

As the authors state in the study conclusion, "Clinical and public health practitioners need to be aware that EV-D68 (while still a concern for children with asthma) can cause severe respiratory illness in otherwise healthy children of all ages, and that hospitalized children with nonasthma underlying conditions may be at higher risk for severe outcomes."

Parents, clinicians, and public health officials face heightened risks during years of elevated EV-D68 circulation. Robust surveillance systems remain essential for identifying emerging respiratory viruses and directing clinical resources during outbreak periods.

More information: Benjamin R. Clopper et al, Enterovirus D68–Associated Respiratory Illness in Children, JAMA Network Open (2025). DOI: 10.1001/jamanetworkopen.2025.9131



https://medicalxpress.com/news/2025-05-enterovirus-infections-linked-severe-respiratory.html

"Rogue" Devices Found Hidden In Chinese Solar Panels Could "Destroy The Grid"

 by Steve Watson via Modernity.news,

Undisclosed communication devices reportedly discovered in Chinese-manufactured solar panels and related equipment have sparked concerns among U.S. officials about the vulnerability of the nation’s power grid, according to a Reuters report. 

These “rogue” devices, found over the past nine months, could potentially destabilize energy infrastructure and trigger widespread blackouts, sources familiar with the matter told the outlet.

The undocumented devices, including cellular radios, were identified in solar power inverters, batteries, electric vehicle chargers, and heat pumps produced by several Chinese suppliers. 

U.S. experts uncovered the components during security inspections of renewable energy equipment, prompting a reevaluation of the risks posed by these products. 

Inverters, critical for connecting solar panels and wind turbines to the power grid, are predominantly manufactured in China, amplifying concerns about their security.

“We know that China believes there is value in placing at least some elements of our core infrastructure at risk of destruction or disruption,” said Mike Rogers, former director of the U.S. National Security Agency.

“I think that the Chinese are, in part, hoping that the widespread use of inverters limits the options that the West has to deal with the security issue,” Roger’s further urged.

Experts warn that these rogue devices could bypass firewalls, allowing remote manipulation of inverter settings or even complete shutdowns. 

Such actions could disrupt power grids, damage energy infrastructure, and cause blackouts. 

“That effectively means there is a built-in way to physically destroy the grid,” another source told Reuters.

The discovery adds to long-standing warnings from energy and security experts about the risks of relying on Chinese-made green energy products. 

Concerns over espionage and sabotage have grown as the U.S. continues to integrate these technologies into its energy systems.

In December 2023, Republican officials, including former Wisconsin Rep. Mike Gallagher and then-Senator Marco Rubio, urged Duke Energy to discontinue using Chinese-manufactured CATL batteries at Camp Lejeune, North Carolina, citing surveillance risks. 

“Directly following our inquiry, Duke disconnected the Chinese-manufactured systems from the grid,” Gallagher and Rubio stated in a February 2024 press release. 

“Others that continue to work with CATL, and other companies under the control of the CCP, should take note,” they added.

The Department of Energy (DOE) acknowledged the issue, with a spokesperson telling Reuters that the department continuously assesses risks associated with new technologies. 

“While this functionality may not have malicious intent, it is critical for those procuring to have a full understanding of the capabilities of the products received,” the spokesperson said. 

The DOE is working to strengthen domestic supply chains and improve transparency through initiatives like the “Software Bill of Materials,” which inventories all components in software applications.

A spokesperson for the Chinese embassy in Washington rejected the allegations, stating, “We oppose the generalisation [sic] of the concept of national security, distorting and smearing China’s infrastructure achievements.”

*  *  *

https://www.zerohedge.com/geopolitical/rogue-devices-found-hidden-chinese-solar-panels-could-destroy-grid

AI Just Took Your Nurse’s Job — Kinda

 Are you ready to get your medical advice from a nurse powered by artificial intelligence (AI)? This is already reality in some healthcare systems. 

I know what you might be thinking: Could AI eventually replace actual nurses and healthcare professionals on advice lines? What about all the potential bad advice and mistakes? 

I have the same thoughts. Let’s discuss. 

AI Nurses Are Already Here

There are some AI tools out there that have nursing unions concerned. I read about one company, Hippocratic AI, which uses clinician-vetted AI chatbots to talk to people about preoperative care, discharge instructions, chronic illness management, and more. 

Now, we already have automated patient messaging, sending people information about procedures, discharge instructions with necessary links, and all that. Imagine if you had these tools and you combine it with language learning models such as ChatGPT and a visual, lifelike AI character. 

This is the case with the company Xoltar, which has AI characters that can speak in different languages and, dare I say, can develop a personalized AI-patient relationship. These chatbots on Xoltar are fully customizable and, according to the company, can offer an engaging, hand-holding experience that can help patients with accountability and influence behavior. I even did a demo and I talked to Carlos, the AI chatbot, all in Spanish, and it was engaging.

Can AI Diagnose Like a Doctor?

These companies have received millions of dollars in venture capital funding and have high-powered partnerships with companies such as Nvidia. And it seems that progress is only growing. 

Even politicians have gotten involved. Robert F. Kennedy, Jr, head of the US Department of Health and Human Services, recently said, “Cincinnati has developed an AI nurse that you cannot distinguish from a human being that has diagnosed as good as any doctor.”

Okay, hold on. Getting a proper diagnosis requires building trust, empathy, and complex thought, and machines are only as good as the information that they’re given. I’m not really sure I agree with RFK Jr on this.

Also, I don’t know what AI nurse he’s speaking of. Mercy Health in Cincinnati does have an AI assistant named Catherine who helps patients navigate knee, shoulder, and hip pain. Perhaps Catherine could free up nurses and medical assistants from all those phone calls so they could then focus on patient care.

Cost Equation: $9 AI v $40 Human Nurse

Hippocratic AI, in partnership with Nvidia, recently released company data showing that its chatbot AI outperformed nurses in identifying toxic dosages of medications, how medications impact lab values, and other tasks. It also highlighted that its chatbot costs $9 an hour compared with the average nursing salary of around $35-$40 an hour. 

Now, the reality is that somewhere some struggling healthcare system may be tempted to pay a lower cost, streamline, and hire fewer actual nurses. 

Red Flags: What Nurses Are Saying

This is just one of the reasons of why nursing unions have organized and spoke out against the rapid expansion of generative AI without thoughtful input from patients and healthcare professionals, and without regulations. 

Some nurses have raised the valid criticism about false positives or alarms raised by AI tools that don’t understand clinical context. We already see this.

For example, we see this with sepsis prediction tools. They may flag a patient who has a fever that we already know about and we’re already treating, or another patient with tachycardia that’s related to a medication side effect or pain. Mistakes and a lack of liability are valid concerns when it comes to AI tools. 

Scribe, Scheduler, Burnout Buster, Maybe

AI tools could do incredible things for our workflow if it helped us with tasks such as paperwork, inputting data into emergency medical record, dictating patient notes, and so much more. Doing things that we don’t really want to do. For example, one company, QVentus, uses AI to hyperanalyze hospital operations and assist in areas such as scheduling. 

There are at least 60 companies using AI to essentially be scribes and help transcribe patient information. One study from Mass General found a 40% reduction in physician burnout during a 6-week pilot of one of these tools, but there was no financial benefit. I guess if we become more efficient at seeing patients thanks to AI tools, shareholders are going to be like, Why don’t you see more patients? That means we’re going to have to address time-based coding to make all these tools actually make sense and be profitable. 

Healthcare Shortcut or Sci-Fi Gamble?

I digress. The growing question is whether generative AI can eventually fill in for nurses and other healthcare professionals. I mean, no one is denying that we have a healthcare professional shortage, especially in rural areas, but are chatbots and AI nurses really the solution? I feel like we’re setting patients up for a science fiction experiment that is evolving faster than any of us can imagine. 

Alok S. Patel, MD, is a pediatric hospitalist, television producer, media contributor, and digital health enthusiast. He is a clinical assistant professor for the department of pediatrics at Stanford Children’s Health in Palo Alto, California. Patel is a special correspondent for ABC News and regularly appears as an on-camera expert for several news outlets. He hosts The Hospitalist Retort video blog on Medscape

https://www.medscape.com/viewarticle/ai-just-took-your-nurses-job-kinda-2025a1000b8q